Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

BACKGROUND: Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking. METHODS: Previously untreated patients with non-resectable mCRC were t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Stein, Alexander, Kretzschmar, Albrecht, Behringer, Dirk, Wolff, Thomas, Zimber, Joachim, Hegewisch-Becker, Susanna, Kettner, Erika, Pflüger, Karl-Heinz, Kirsch, Andreas, Arnold, Dirk
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3850951/
https://ncbi.nlm.nih.gov/pubmed/24090011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-454
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items